Accesswire
30 Jun 2026, 00:00 UTC · 12w ago
Verdict
Headline takes no side. We score MIR +0.20 across four claims — slightly bullish.
+0.20slightly bullish
More positive than 53% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
All long and short term debts are currently under negotiation to restructure terms and conditions of repayment.
More negative than 99% of claims this week
MedMira has completed the second phase of clinical trials for its Multiplo Complete Syphilis Antibody Test and will submit the data to support its regulatory application.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 86% of claims this week
The company has initiated the regulatory approval process for its products in Australia and selected EMEA markets via the Mutual Recognition Agreement.
More positive than 77% of claims this week
Q3 FY2026 revenue increased to $241,189 from $24,503 in the previous quarter.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 53% of ticker scores this week
The company showed revenue growth and progress in regulatory approvals, but continues to report net losses and has debts under restructuring.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
2h ago
−6.2%
Price is moving against the score
$16.38 vs $17.46 close before publication (Jun 29) · not market-adjusted
MIR chart →
